Boosting Domestic MedTech: Strategic Expansion of the PLI Scheme for Medical Devices

In a decisive push toward achieving ‘Atmanirbhar Bharat’ in the healthcare sector, the Union Government has invited fresh applications under the Production Linked Incentive (PLI) scheme for medical devices. The initiative, now extended through the 2035–36 fiscal period, represents a strategic evolution in India’s industrial policy, aimed at reducing the nation’s heavy reliance on high-end medical equipment imports. By fostering a domestic manufacturing ecosystem, the government seeks to secure supply chains for critical diagnostic and therapeutic devices, thereby insulating the public health sector from global supply chain volatility.

The revamped framework focuses on simplifying eligibility criteria and streamlining administrative processes. This procedural overhaul is designed to improve the ‘Ease of Doing Business,’ making it more attractive for both domestic players and foreign investors to establish high-end manufacturing units within India. Historically, India’s medical device market has been dominated by imports, particularly in the categories of advanced imaging, surgical robotics, and life-support systems. This incentive-based intervention addresses the structural challenges of high capital expenditure and technological gaps, encouraging the private sector to move up the value chain from low-end disposables to sophisticated medical hardware.

For the Indian economy, the success of this scheme is crucial for balancing the trade deficit in the health sector while simultaneously generating high-skilled employment. By incentivizing R&D and local manufacturing, India aims to become a global hub for medical technology, catering not only to its burgeoning domestic healthcare needs—driven by an aging population and rising lifestyle diseases—but also to the growing demand for affordable medical technology in the Global South. The extension of the timeline until 2035-36 provides the long-term policy certainty required by manufacturers to make sustained capital investments, ensuring that policy implementation keeps pace with rapidly evolving global standards in medical innovation.